what about TXMD , buy, sell or hold ?

**Sell** TherapeuticsMD (TXMD) with **high caution**. The stock faces **significant challenges**, including **negative earnings**, a **high P/E ratio**, and **weak revenue growth**, outweighing its **recent insider purchase activity**. Below is a detailed analysis to guide your decision. --- ### **Financial Health** | Metric | Data (Q1 2025) | Implication | |----------------|-------------------|--------------------------------------------| | **Net Income** | -$653,000 | Continued losses highlight operational challenges. | | **Revenue** | $393,000 | Weak revenue growth of 25.56% YoY suggests limited market traction. | | **Diluted EPS** | -$0.06 | Negative EPS indicates unprofitability. | **Key Takeaway**: TXMD’s financials are **weak**, with no signs of profitability or meaningful revenue growth. --- ### **Valuation Metrics** | Metric | Data (2025-07-21) | Implication | |----------------|-------------------|--------------------------------------------| | **P/E Ratio** | -6.34 | Extremely negative P/E suggests the stock is not valued for earnings. | | **Price-to-Sales Ratio** | 7.23 | High P/S ratio indicates the market is paying a premium for sales. | | **Price-to-Book Ratio** | 0.5 | Low P/B ratio suggests the market values the company’s assets poorly. | **Key Takeaway**: TXMD’s valuation metrics are **distorted** by its negative earnings and lack of revenue growth. --- ### **Technical Analysis** | Metric | Data (2025-07-21) | Implication | |----------------|-------------------|--------------------------------------------| | **Closing Price** | $1.16 | Trading near its 52-week low of $1.13, indicating bearish momentum. | | **Moving Averages** | 5-day ($1.18), 10-day ($1.20), 20-day ($1.15) | Short-term moving averages suggest downward pressure. | **Key Takeaway**: TXMD’s technical indicators are **bearish**, with the stock trading below short-term moving averages. --- ### **Insider Activity** | Metric | Data (2025-04-22) | Implication | |----------------|-------------------|--------------------------------------------| | **Insider Purchase** | CEO Marlan Walker bought $489 worth of stock at $0.9985 per share. | This signals a **potential belief in value**, but limited by the small purchase amount. | **Key Takeaway**: The insider purchase is a **positive signal**,